NDAINTRAVENOUSSOLUTION
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
COMBOGESIC IV (acetaminophen and ibuprofen injection) by Hikma is cyclooxygenase inhibitors [moa]. Approved for nonsteroidal anti-inflammatory drug [epc], moderate to severe pain, less. First approved in 2023.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBOGESIC IV is a fixed-dose intravenous combination of acetaminophen and ibuprofen approved in October 2023 for moderate to severe pain. It works through cyclooxygenase inhibition to provide dual analgesic and anti-inflammatory effects via the nonsteroidal anti-inflammatory drug (NSAID) class. This IV formulation targets acute pain settings where rapid, parenteral administration is clinically advantageous.
Growth9.7 years to LOE
Early-stage growth-phase product with emerging market presence and expanding organizational investment in commercial infrastructure.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications (2)
Worked on COMBOGESIC IV at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.